{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:45:33Z","timestamp":1791179133002,"version":"4.1.0"},"reference-count":37,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2005,10,27]],"date-time":"2005-10-27T00:00:00Z","timestamp":1130371200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2006,1]]},"abstract":"<jats:p><jats:bold>Abstract:\u2002<\/jats:bold>  <jats:italic>Objectives:<\/jats:italic> Mantle cell lymphoma (MCL) is an incurable disease with an aggressive course and novel treatment strategies are urgently needed. The purpose of this study was to evaluate the effects of histone deacetylase (HDAC) inhibitors, a new group of antiproliferative agents, on human MCL cells. <jats:italic>Methods:<\/jats:italic> Three MCL cell lines (JeKo\u20101, Hbl\u20102 and Granta\u2010519) were exposed to different concentrations of the HDAC inhibitors sodium butyrate (NaB) and suberoylanilide hydroxamic acid (SAHA) for 8\u201372\u2003h. Their effects on cell viability, apoptosis induction and cell cycle proliferation were studied. Moreover, the influence of SAHA on the expression of cyclin D1, the cell cycle regulators p21 and p27 and the production of vascular endothelial growth factor (VEGF) were analyzed. <jats:italic>Results:<\/jats:italic> The HDAC inhibitors induced accumulation of acetylated histones in MCL cells. MTT assays and Annexin\u2010V staining showed that they potently inhibited viability in a dose\u2010dependent manner and induced apoptosis in all cell lines tested. Cell cycle analysis indicated that their exposure to SAHA or NaB decreased the proportion of cells in S phase and increased the proportion of cells in the G0\/G1 and\/or G2\/M phases. Incubation with the two HDAC inhibitors resulted in downregulation of cyclin D1. SAHA lead to an upregulation of p21 in all cell lines and an upregulation of p27 in JeKo\u20101 and Granta\u2010519 cells, while expression of p27 in Hbl\u20102 was not altered. In addition, SAHA inhibited the production of the angiogenic cytokine VEGF. Treatment with NaB increased the expression of p21 in JeKo\u20101 and Hbl\u20102 cells, while in Granta 519 cells no effect was noted. The expression of p27 remained constant in all three cell lines after exposure to NaB. <jats:italic>Conclusion:<\/jats:italic> Based on these findings, we provide evidence that HDAC inhibitors have antiproliferative effects in MCL and may represent a promising therapeutic approach.<\/jats:p>","DOI":"10.1111\/j.1600-0609.2005.00546.x","type":"journal-article","created":{"date-parts":[[2005,10,27]],"date-time":"2005-10-27T12:36:33Z","timestamp":1130416593000},"page":"42-50","source":"Crossref","is-referenced-by-count":69,"title":["Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma"],"prefix":"10.1111","volume":"76","author":[{"given":"Ulrike","family":"Heider","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Sterz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Zavrski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Jakob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Fleissner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Eucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"Possinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orhan","family":"Sezer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,10,27]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V76.10.2086.2086"},{"key":"e_1_2_5_3_2","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","article-title":"The Non\u2010Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non\u2010Hodgkin's lymphoma","volume":"89","year":"1997","journal-title":"Blood"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001622-200109000-00005"},{"key":"e_1_2_5_5_2","first-page":"662","article-title":"Histone deacetylase inhibitors: a new class of potential therapeutic agents for cancer treatment","volume":"8","author":"Richon VM","year":"2002","journal-title":"Clin Cancer Res"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/35895"},{"key":"e_1_2_5_9_2","first-page":"3697","article-title":"Induction of caspase\u20103 protease activity and apoptosis by butyrate and trichostatin A (inhibitors of histone deacetylase): dependence on protein synthesis and synergy with a mitochondrial\/cytochrome c\u2010dependent pathway","volume":"57","author":"Medina V","year":"1997","journal-title":"Cancer Res"},{"key":"e_1_2_5_10_2","first-page":"4392","article-title":"Hybrid polar histone deacetylase inhibitor induces apoptosis and CD95\/CD95 ligand expression in human neuroblastoma","volume":"59","author":"Glick RD","year":"1999","journal-title":"Cancer Res"},{"key":"e_1_2_5_11_2","first-page":"5165","article-title":"Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo","volume":"60","author":"Butler LM","year":"2000","journal-title":"Cancer Res"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-200209000-00013"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-03-0100"},{"key":"e_1_2_5_14_2","first-page":"5749","article-title":"Histone deacetylase inhibitors induce growth suppression and cell death in human rhabdomyosarcoma in vitro","volume":"9","author":"Kutko CCR","year":"2003","journal-title":"Clin Cancer Res"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2000.02207.x"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.78.9.4582-4590.2004"},{"key":"e_1_2_5_17_2","first-page":"5018","article-title":"Induction of apoptosis by apicidin, a histone deacetylase inhibitor, via the activation of mitochondria\u2010dependent caspase cascades in human Bcr\u2010Abl\u2010positive leukemia cells","volume":"9","author":"Cheong JW","year":"2003","journal-title":"Clin Cancer Res"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.1174"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-11-3514"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-03-0561"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/35106079"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.180316197"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-291X(02)02787-0"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2004.02.105"},{"key":"e_1_2_5_25_2","first-page":"2899","article-title":"Immunohistochemical detection of C\u2010kit (CD117) and vascular endothelial growth factor (VEGF) overexpression in mantle cell lymphoma","volume":"22","author":"Potti A","year":"2002","journal-title":"Anticancer Res"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1053\/adpa.2003.50000"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.9.2865"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.2174\/1381612043383980"},{"key":"e_1_2_5_29_2","first-page":"3578","article-title":"Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously","volume":"9","author":"Kelly WK","year":"2003","journal-title":"Clin Cancer Res"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19880201)61:3<483::AID-CNCR2820610313>3.0.CO;2-L"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddh195"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1097\/00062752-200207000-00010"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-01-0233"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.04882.x"},{"key":"e_1_2_5_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2400555"},{"key":"e_1_2_5_36_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00911.x"},{"key":"e_1_2_5_37_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V86.3.841.841"},{"key":"e_1_2_5_38_2","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.4049\/jimmunol.161.3.1123","article-title":"A pivotal role of cyclin D3 and cyclin\u2010dependent kinase inhibitor p27 in the regulation of IL\u20102\u2010, IL\u20104\u2010, or IL\u201010\u2010mediated human B cell proliferation","volume":"161","author":"Wagner EF","year":"1998","journal-title":"J Immunol"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.2005.00546.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0609.2005.00546.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T04:35:16Z","timestamp":1695789316000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.2005.00546.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,10,27]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,1]]}},"alternative-id":["10.1111\/j.1600-0609.2005.00546.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.2005.00546.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,10,27]]}}}